TickerSpark Feed

fda catalyst

Everything tagged "fda catalyst" across research, earnings, and macro.

2 articles

Summit’s giant insider buy says the stock offering didn’t break the ivonescimab story

Summit’s financing headline looks ugly, but the insider tape says management is still leaning into ivonescimab rather than backing away from it. When co-CEOs and the CFO buy more than $100 million of stock right into a raise, dilution stops looking like the whole story.

Jun 15, 2026·4 MIN

Biotechnology Insider Buying FDA Catalyst

OpinionSMMT

Summit Therapeutics is getting punished like a broken biotech when the real issue is financing

Summit Therapeutics is trading like ivonescimab broke, but the key catalyst is still on the calendar. The market is hammering SMMT for financing and credibility risk, and that distinction matters because those are fixable problems while the November 2026 FDA decision remains alive.

Jun 2, 2026·4 MIN

Biotechnology FDA Catalyst Financing Risk

On-Demand Research

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator